Browsing Tag
NeuroSense Therapeutics Ltd.
2 posts
NeuroSense Therapeutics (NASDAQ: NRSN) extends PrimeC exclusivity to 2042 with Australian patent as Phase 3 focus intensifies
Find out how NeuroSense Therapeutics’ Australian patent grant strengthens PrimeC’s long-term outlook as the ALS program advances toward Phase 3.
NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough?
NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next.